Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ClearPoint Neuro Inc Market Cap
Based on ratings from 0 stock analysts, the ClearPoint Neuro Inc stock price is expected to decrease by 0.08% in 12 months. This is calculated by using the average 12-month stock price forecast for ClearPoint Neuro Inc. The lowest target is $10 and the highest is $15. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedCLPT 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect ClearPoint Neuro Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CLPT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CLPT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Frank Takkinen Lake Street | Buy | $15 | Maintains | Aug 27, 2024 |
| Mathew Blackman Stifel | Buy | $9 | Reiterates | Mar 13, 2024 |
| Mathew Blackman Stifel | Buy | $8 | Initiates | Oct 24, 2023 |
| Frank Takkinen Lake Street | Buy | $15 | Maintains | Aug 9, 2023 |
| Neil Chatterji B. Riley Securities | Buy | $14 | Reinstates | Feb 16, 2023 |
| Marc Wiesenberger B. Riley Securities | Buy | $15 | Reinstates | Apr 5, 2022 |
| Frank Takkinen Lake Street | Buy | $32 | Initiates | Mar 18, 2021 |
B. Riley Securities | Buy | Initiates | Jul 17, 2020 |
When did it IPO
N/A
Staff Count
107
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Joseph Michael Burnett
Market Cap
$351.8M
In 2023, CLPT generated $24.0M in revenue, which was a increase of 16.56% from the previous year. This can be seen as a signal that CLPT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics
Wed, 14 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Kyle Bauser - B. Riley Emily Christy - Stifel Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2024 Financial Results Conference Call.
Wed, 07 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
Thu, 08 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its products part of FDA submissions. Continuous growth is expected through partner programs, consulting fees, and possible royalties and milestone payments.
Wed, 31 Jul 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
